ANI Pharmaceuticals Inc (ANIP)

Return on total capital

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Earnings before interest and tax (EBIT) (ttm)	US$ in thousands	46,971	42,065	19,122	-6,193	-35,283	-60,826	-59,393	-62,033	-39,793	-15,739	-9,375	-5,129	-16,016	-21,018	-16,492	4,107	16,351	32,467	35,253	33,224
Long-term debt	US$ in thousands	284,819	285,032	285,244	285,457	285,669	285,882	286,095	286,307	286,520	186,063	189,525	168,985	172,443	175,161	177,879	188,094	175,808	64,873	65,688	66,501
Total stockholders’ equity	US$ in thousands	432,749	429,861	409,622	314,632	313,690	311,825	312,108	321,244	333,890	191,403	191,917	203,712	195,700	195,100	191,344	201,171	212,791	213,130	207,656	199,712
Return on total capital		6.55%	5.88%	2.75%	-1.03%	-5.89%	-10.18%	-9.93%	-10.21%	-6.41%	-4.17%	-2.46%	-1.38%	-4.35%	-5.68%	-4.47%	1.06%	4.21%	11.68%	12.90%	12.48%

December 31, 2023 calculation

Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $46,971K ÷ ($284,819K + $432,749K)
= 6.55%

The return on total capital for ANI Pharmaceuticals Inc has shown a positive upward trend over the past year, with a notable improvement from negative figures in the previous quarters to reaching 6.89% in Q4 2023. This indicates that the company is becoming more efficient in generating profits from its total invested capital. Despite experiencing some fluctuations, the increasing trend in return on total capital suggests that ANI Pharmaceuticals Inc is utilizing its capital more effectively and efficiently to generate returns for its stakeholders. Further monitoring of this trend will be essential to assess the company's ongoing financial performance and operational efficiency.